|
000
| 01325nam 2200301za 4500 |
|---|
| 001 | 9.847586 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107153457 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171122s2018 onca o f000 0 eng d |
|---|
| 020 | |a9780660239637|z9780660239644 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-175/2017E-PDF |
|---|
| 110 | 2 |aNational Research Council Canada. |
|---|
| 245 | 10|aImmunomodulator for asthma treatment (L-11894) |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c[2018] |
|---|
| 300 | |a[1] p. : |bcol. ill. |
|---|
| 500 | |aIssued also in French under title: Immunomodulateur pour le traitement de l’asthme (L-11894). |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"December 2017." |
|---|
| 520 | |a“To address the need for a safe, disease-modifying treatment, the NRC has developed an immunomodulator that suppresses the unbalanced immune response that causes asthma”--Highlights. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aImmunological adjuvants |
|---|
| 693 | 4|aAsthma |
|---|
| 775 | 08|tImmunomodulateur pour le traitement de l’asthme (L-11894) |w(CaOODSP)9.847589 |
|---|
| 776 | 0#|tImmunomodulator for asthma treatment |w(CaOODSP)9.847588 |
|---|
| 856 | 40|qPDF|s176 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-175-2017-eng.pdf |
|---|